Cystatin C (CysC), a low-molecular-weight protein, is widely used as a biomarker of renal function. The relationship between CysC and cognitive impairment remains controversial. This study aimed to investigate the association between CysC and cognitive impairment in the Hanzhong Adolescent Hypertension Study.
Methods
A total of 2,347 participants completed the Mini-Mental State Examination (MMSE) in 2023, after excluding the participants missing data, 1929 participants were included. Multivariable logistic regression was used to assess the cross-sectional association between serum CysC levels and cognitive impairment. Subgroup and interaction analyses were performed to examine effect modification by albuminuria status. The nonlinear relationship was explored using restricted cubic splines (RCS).
Results
Cognitive impairment was identified in 149 participants (7.72%). Each 1-SD increase in CysC levels was significantly associated with 49% higher odds of cognitive impairment after full adjustment [odds ratio (OR) = 1.49, 95% confidence interval (CI): 1.24–1.79, p < 0.001]. Compared with participants in the lowest CysC quartile, those in the highest quartile had significantly higher odds of cognitive impairment (OR = 1.79, 95% CI = 1.09–2.98, p = 0.022). The association was stronger in participants without albuminuria (OR per SD = 1.48, 95% CI: 1.22–1.80, p < 0.001) but absent in those with albuminuria (OR per SD = 1.00, 95% CI: 0.73–1.25, p = 0.981), with a significant interaction when CysC was modeled continuously (p for interaction = 0.028). A linear and positive association was observed between cystatin C levels and the prevalence of cognitive impairment (p for linearity < 0.001). This association remained significant in the non-albuminuria subgroup.
Conclusion
Elevated CysC is associated with cognitive impairment assessed by MMSE in this midlife natural population cohort. This association is stronger in participants without albuminuria.
albuminuriacognitive impairmentcystatin ChypertensionMMSEThe author(s) declared that financial support was received for this work and/or its publication. This work was supported by the National Natural Science Foundation of China No. 82200472 (WZ), the Key Research and Development Program of ShaanXi (2023-ZDLSF-50), the Clinical Research Award of the First Affiliated Hospital of Xi’an Jiaotong University of China (grant No. XJTU1AF-CRF-2023-004 and XJTU1AF-CRF-2024-003).section-at-acceptanceDementia and Neurodegenerative DiseasesIntroduction
Dementia, a condition secondary to neurodegenerative and psychiatric diseases, represents a growing global health challenge that significantly impairs quality of life (1, 2). Its prevalence is increasing by approximately 10 million cases annually. Cognitive impairment is widely recognized as a preclinical and transitional stage of dementia (3), primarily characterized by declines in attention, learning, memory, and related abilities (4). Notably, research in N Engl J Med and the Lancet suggests that Alzheimer’s disease and dementia may originate in midlife (5, 6). Consequently, early detection, prevention, and treatment of cognitive impairment within the middle-aged population offer a critical opportunity to delay dementia progression (3, 7).
Evidence highlighted by the World Health Organization (WHO) and The Lancet indicates that the development of cognitive impairment and dementia is strongly associated with modifiable risk factors. These encompass unhealthy lifestyle choices, such as physical inactivity, smoking, and excessive alcohol consumption, as well as chronic conditions including hypertension, diabetes, and hyperlipidemia (1, 2). Advances in basic medical research have identified classic biomarkers of cognitive impairment, such as amyloid-β, phosphorylated tau, and total tau. Additionally, novel biomarkers including NPTX2 and pro-inflammatory chemokines continue to emerge (8–10). However, the absence of a definitive biomarker for predicting mild cognitive impairment led Pu et al. to develop a nomogram incorporating demographic characteristics, health status, and behavioral data to identify potential predictors (11). Despite these efforts, current detection methods and biomarkers face significant limitations in clinical applicability, underscoring the need for feasible biomarkers to facilitate early intervention.
Cystatin C (CysC), a low-molecular-weight protein produced by nucleated cells, freely traverses the glomerular membrane (12). Since the 1980s, its high sensitivity for detecting impaired renal function (12, 13) has established CysC as a superior marker for estimating glomerular filtration rate (GFR) (14, 15). Meta-analyses by Nair and Yang et al. reported elevated CysC levels in individuals with MCI comorbid with Parkinson’s disease (16, 17). Nevertheless, the relationship between CysC levels and MCI in the natural population remains unclear.
Therefore, this cross-sectional study aims to investigate the association between serum CysC levels and cognitive impairment, and to explore whether this association is independent of renal function (eGFR) and blood pressure, in a natural adult population. Our findings may offer preliminary clues regarding the link between vascular/metabolic factors and cognitive function, which could inform the design of future longitudinal studies aimed at risk prediction.
MethodsStudy design and participants
This study is a cross-sectional analysis. We utilized data from the most recent follow-up in 2023 of the Hanzhong Adolescent Hypertension Study. Details regarding the cohort design have been published previously (18–20). A total of 4,623 Chinese children in 3 towns (Qili, Laojun, and Shayan) were included in this cohort at baseline, which included 26 rural sites in Hanzhong City of Shaanxi province. Participants met these inclusion criteria: no chronic disease history, Mandarin-speaking ability, and voluntary participation. We excluded those with pre-existing chronic conditions or whose parents/guardians declined involvement.
Over 36 years, participants were followed through seven waves: 1989, 1992, 1995, 2005, 2013, 2017, and 2023. While most waves targeted all available participants, the 2005 assessment used systematic sampling (every tenth participant; n = 436) as detailed previously (19). Response rates fluctuated across follow-ups: 77.7% (n = 3,592) in 1989, 84.8% (n = 3,918) in 1992, 82.1% (n = 3,794) in 1995, 65.3% (n = 3,018) in 2013, 60.1% (n = 2,780) in 2017, and 56.7% (n = 2,621) in 2023.
The study complies with the Declaration of Helsinki and received ethical approval from the First Affiliated Hospital of Xi’an Jiaotong University (Code: XJTU1AF2015LSL-047). All participants provided written informed consent at each visit (parental/guardian consent for minors). We adhered to STROBE guidelines for observational studies (ClinicalTrials.gov ID: NCT02734472).
Figure 1 illustrates the flow of participant inclusion and exclusion. Given the substantial amount of missing data and concerns that the data were not missing completely at random, we chose to perform a complete-case analysis rather than multiple imputation to avoid introducing bias. Specifically, 2,347 participants completed the Chinese version of the Mini-Mental State Examination (MMSE) and had educational level data available at the 2023 follow-up (Visit 8). We applied exclusions: (1) CysC data missing (n = 180); (2) uACR data missing (n = 177); (3) personal information (including age and marriage status) missing (n = 204); (4) Lifestyle factors data (including physical activity, smoking status and alcohol consumption) missing (n = 4); (5) History of diseases [including stroke and CHD (coronary heart disease)] missing (n = 8); (6) Biochemical result (including FBG, TG, LDL-C and eGFR) missing (n = 348). The final analytical cohort included 1929 participants. Supplementary Table S1 compares the characteristics of excluded and included participants; no substantial differences that would introduce selection bias were observed.
Flowchart for inclusion and exclusion.
Flowchart of the Hanzhong Adolescent Hypertension Study process. Established in 1987 with 4,623 participants. By 2023, 2,612 followed up. 2,347 had complete MMSE and educational data. Exclusions totaled 418, including missing CysC and uACR data, personal information, lifestyle factors, disease history, and biochemical results. Final analysis included 1,929 participants.Data collection
This cross-sectional analysis utilized data from the most recent follow-up survey conducted in 2023. The following data were collected: Demographics/lifestyle, including age, sex, education, smoking, alcohol drinking and history of diseases via structured questionnaires; Blood pressure was measured three times in the seated position using mercury sphygmomanometers (19, 21, 22). Height, weight, and waist circumference were measured by trained investigators. Refer to the guidelines for dementia and cognitive impairment in China: the diagnosis and treatment of mild cognitive impairment (23) and previous studies on the Chinese population.
Blood and urine biochemical analyses
We obtained fasting blood and urine samples through peripheral venous puncture and measured biochemical indicators including lipoprotein (a), CysC, fasting blood glucose, total bilirubin, glutamic pyruvic transaminase, glutamic oxaloacetic transaminase, serum creatinine, serum uric acid, total cholesterol, triglyceride, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), urinary microalbumin and urinary creatinine using the automatic biochemical analyzer (Hitachi, Tokyo, Japan) as described previously (24–26).
Definitions
Refer to the guidelines for dementia and cognitive impairment in China: the diagnosis and treatment of mild cognitive impairment (23) and previous studies on the Chinese population, the cut-off MMSE score points in our research for detecting cognitive impairment are 17 for illiterate individuals, 20 for individuals with 1–6 years of education, and 24 for individuals with 7 or more years of education (27–29). Hypertension was defined as prior diagnosis of hypertension with or without using anti-hypertensives or BP ≥ 140/90 mmHg in 2023 (visit 8). eGFR = 175 × serum creatinine− 1.234 × age− 0.179 (×0.79 for female). Given the role of CysC in assessing early kidney injury, we stratified participants by albuminuria status (uACR [urinary albumin-to-creatinine ratio] ≥ 30 mg/g) to determine kidney injury status (20, 30, 31).
Covariates
To control for potential confounding effects, the following covariates were included in the multivariable models: (1) Sociodemographic and behavioral characteristics: Gender, age, marital status, physical activities, smoking habits, alcohol consumption; (2) Anthropometric parameters: BMI, mean BMI, mean SBP; (3) Clinical history: stroke, coronary heart disease (CHD); (4) Biochemical assays: fasting blood glucose (FBG), triglyceride (TG), LDL-C and eGFR.
Statistical analyses
Median with interquartile ranges (IQR) was used to describe the continuous variables, and the Mann–Whitney U-test was used to assess the group differences. Frequency and percentage were used to describe the categorical variables, and the chi-square test assessed group differences.
We used multiple logistic regression to examine the association between CysC levels and cognitive impairment as odds ratios (ORs) with corresponding 95% confidence intervals (CIs). The models followed a sequential adjustment strategy: (1) Model 1 was unadjusted; (2) Model 2 was adjusted for basic demographic and clinical factors, including age, gender, mean SBP, and mean BMI; (3) Model 3 further extended the adjustment by incorporating the covariates from Model 2 plus additional variables pertaining to lifestyle, cardiovascular history, and extended biochemical profiles, specifically: marital status, physical activities, smoking habits, alcohol consumption, stroke, CHD, FBG, TG, LDL-C, and eGFR.
We calculated Pearson correlation coefficients between CysC and all covariates (Supplementary Table S2). The variance inflation factor (VIF) was computed to assess multicollinearity; values below 10 indicate the absence of severe multicollinearity. The correlation between CysC and eGFR was −0.288, with corresponding VIF values of 1.13 for CysC and 1.15 for eGFR.
To further explore the heterogeneity in the association between CysC and cognitive impairment, we conducted subgroup and interaction analyses. CysC and albuminuria serve as biomarkers for detecting early renal impairment in individuals with preserved or mildly reduced eGFR (20, 30, 31). This study cohort comprised a natural population sample, with a limited number of participants with eGFR < 90 mL/min/1.73 m2. Consequently, the association between serum CysC levels and cognitive impairment was examined, stratified by albuminuria status (uACR < 30 mg/g vs. ≥ 30 mg/g). In the interaction analysis, the likelihood ratio test was used to assess the significance of interaction effects. Furthermore, to account for the potential confounding effects of gender, age, alcohol consumption, and chronic conditions on cognitive function, subgroup analyses were stratified by these variables. The potential nonlinear relationship between CysC and cognitive impairment was evaluated using restricted cubic splines (RCS) with 3 knots placed at the 10th, 50th, and 90th percentiles. In both the subgroup and RCS analyses, all covariates included in Model 3 were adjusted for as potential confounders, except for the stratification variable itself in the subgroup analyses. To enhance the robustness of the findings, we platformed the sensitivity analysis after excluding the participants receiving pharmacological treatment for hypertension, diabetes, or dyslipidemia. Data processing and analysis were performed using R (version 4.5.1) or Stata (version 17.0), p-values < 0.05 were considered statistically significant.
ResultsThe characteristics of the participants grouped according to cognitive impairment
A total of 1,929 participants were included in this study, of whom 1,077 (45.89%) were female. The median age was 49 (32–37) years. The median serum CysC level was 1.03 (0.88–1.19) mg/L. Based on its distribution, CysC was categorized into quartiles: Q1 (<0.88 mg/L), Q2 (0.88 to <1.03 mg/L), Q3 (1.03 to <1.19 mg/L), and Q4 (≥1.19 mg/L). CysC levels were also standardized (converted to z-scores) for some analyses. Cognitive impairment was identified in 149 participants (7.72%).
Table 1 summarizes demographic, clinical, and laboratory characteristics of participants with and without cognitive impairment. Compared to cognitively normal participants, those with cognitive impairment were significantly older. They also demonstrated higher mean SBP and mean BMI over the 36-year follow-up period. Furthermore, participants with cognitive impairment exhibited significantly higher levels of Lp(a) and CysC. Lower urinary creatinine levels and significantly lower MMSE scores were also observed in the cognitive impairment group.
Characteristics of participants grouped by cognitive impairment.
Variable
Total (n = 1929)
Without cognitive impairment (n = 1780)
With cognitive impairment (n = 149)
p-value
Age, years
49 (45–50)
48 (45–50)
50 (48–51)
<0.001
SBP, mmHg
125 (114.5–136.5)
125 (114–136.5)
127.5 (117–140)
0.046
DBP, mmHg
83 (75–91)
83 (75–91)
82.5 (77–91)
0.481
HR, beats/min
77 (70.33–85)
77 (70.67–85.33)
77 (69.5–84)
0.856
MeanSBP, mmHg
116.43 (109.9–124.09)
116.28 (109.79–123.79)
119.62 (110.84–128.68)
0.006
Mean BMI, kg/m2
21.38 (19.8–22.86)
21.36 (19.77–22.81)
21.85 (20.25–23.6)
0.011
CysC, mg/L
1.03 (0.88–1.19)
1.03 (0.88–1.19)
1.1 (0.92–1.29)
<0.001
Fasting insulin, mU/L
14.67 (11.75–18.82)
14.65 (11.65–18.83)
15.25 (12.16–18.66)
0.600
hs-CRP, mg/L
0.68 (0.33–1.49)
0.68 (0.33–1.48)
0.68 (0.34–1.69)
0.718
FBG, mmol/L
5.31 (4.95–5.78)
5.31 (4.95–5.78)
5.36 (5.03–5.94)
0.194
Serum Cre, μmol/L
73.3 (64.6–82.1)
73.4 (64.6–82.03)
71.9 (63.3–82.2)
0.705
Serum UA, μmol/L
282 (232.5–337.6)
282.6 (232.07–338.3)
279.5 (236.5–335.2)
0.975
TC, mmol/L
4.73 (4.24–5.3)
4.73 (4.24–5.29)
4.77 (4.21–5.38)
0.542
TG, mmol/L
1.57 (1.12–2.25)
1.57 (1.13–2.26)
1.48 (1.08–2.16)
0.269
HDL, mmol/L
1.13 (0.98–1.31)
1.13 (0.98–1.31)
1.14 (0.98–1.36)
0.656
LDL, mmol/L
2.63 (2.23–3.05)
2.62 (2.23–3.05)
2.69 (2.27–3.08)
0.603
Lp(a), mg/L
160 (91–272)
159 (90–266.25)
182 (112–318)
0.020
MMSE score
28 (26–29)
28 (27–29)
24 (22–24)
<0.001
eGFR, mL/min/1.73m2
99.5 (90.9–110)
99.5 (91.07–110)
99 (89.6–110)
0.754
uACR, mg/g
4.66 (1.79–14.02)
4.6 (1.81–13.71)
6.65 (1.74–20.95)
0.181
Gender
0.864
Female
891 (46.19%)
821 (46.12%)
70 (46.98%)
Male
1,038 (53.81%)
959 (53.88%)
79 (53.02%)
Smoking, n (%)
0.931
No
1,162 (60.24%)
1,073 (60.28%)
89 (59.73%)
Yes
767 (39.76%)
707 (39.72%)
60 (40.27%)
Drinking, n (%)
0.033
No
1,423 (73.77%)
1,302 (73.15%)
121 (81.21%)
Yes
506 (26.23%)
478 (26.85%)
28 (18.79%)
Married status, n (%)
0.087
Unmarried
13 (0.67%)
11 (0.62%)
2 (1.34%)
Married
1839 (95.33%)
1,695 (95.22%)
144 (96.64%)
Divorced
62 (3.21%)
61 (3.43%)
1 (0.67%)
Widowed
15 (0.78%)
13 (0.73%)
2 (1.34%)
Physical activities, n (%)
0.008
No activity
237 (12.29%)
224 (12.58%)
13 (8.72%)
Mild
799 (41.42%)
751 (42.19%)
48 (32.21%)
Moderate
675 (34.99%)
614 (34.49%)
61 (40.94%)
Vigorous
218 (11.30%)
191 (10.73%)
27 (18.12%)
Education, n (%)
<0.001
Illiteracy
1 (0.05%)
1 (0.06%)
0 (0.00%)
Primary school
142 (7.36%)
133 (7.47%)
9 (6.04%)
Junior high school
1,158 (60.03%)
1,043 (58.60%)
115 (77.18%)
High/secondary school
413 (21.41%)
392 (22.02%)
21 (14.09%)
Post-secondary education
213 (11.04%)
209 (11.74%)
4 (2.68%)
Master’s degree or higher
2 (0.10%)
2 (0.11%)
0 (0.00%)
Stoke, n (%)
0.664
No
1909 (98.96%)
1762 (98.99%)
147 (98.66%)
Yes
20 (1.04%)
18 (1.01%)
2 (1.34%)
CHD, n (%)
1.000
No
1924 (99.74%)
1775 (99.72%)
149 (100.00%)
Yes
5 (0.26%)
5 (0.28%)
0 (0.00%)
Hypertension, n (%)
0.108
No
1,248 (64.70%)
1,161 (65.22%)
87 (58.39%)
Yes
681 (35.30%)
619 (34.78%)
62 (41.61%)
Diabetes, n (%)
0.880
No
1763 (91.39%)
1,627 (91.40%)
136 (91.28%)
Yes
166 (8.61%)
153 (8.60%)
13 (8.72%)
Hyperlipidemia, n (%)
0.551
No
960 (49.77%)
882 (49.55%)
78 (52.35%)
Yes
969 (50.23%)
898 (50.45%)
71 (47.65%)
Drug treatment, n (%)
0.334
No
1,646 (85.33%)
1,523 (85.56%)
123 (82.55%)
Yes
283 (14.67%)
257 (14.44%)
26 (17.45%)
Albuminuria, n (%)
0.104
No
1,668 (86.47%)
1,546 (86.85%)
122 (81.88%)
Yes
261 (13.53%)
234 (13.15%)
27 (18.12%)
HR, heart rate; SBP, systolic blood pressure; DBP, diastolic blood pressure; Mean SBP, mean SBP of 36 years; BMI, body mass index; MMSE, Mini-Mental State Examination; CysC, cystatin C; hs-CRP, high-sensitivity C-reactive protein; FBG, fasting blood glucose; Cre, Creatinine; UA, uric acid; TC, total cholesterol; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; eGFR, estimated glomerular filtration rate; uACR, urinary microalbumin-to-creatinine ratio. Bold p-values indicate statistically significant differences.
Association between CysC levels and cognitive impairment
Table 2 presents the association between midlife CysC levels and cognitive impairment. In the unadjusted model, each SD increase in CysC level was significantly associated with greater odds of cognitive impairment (OR = 1.43, 95% CI: 1.22–1.68; p < 0.001). This association persisted in the full adjustment model (adjusted OR = 1.49, 95% CI: 1.24–1.79; p < 0.001). Participants in the highest CysC quartile had 1.79-fold greater odds of cognitive impairment compared to the lowest quartile (adjusted OR = 1.79 95% CI: 1.09–2.98; p = 0.022). Complete specifications of the multiple regression models, including model equations, are provided in Supplementary Table S3. Supplementary Table S4 shows the association between CysC and cognitive impairment without adjustment for eGFR.
ORs and 95% CIs of cognitive impairment.
Variable
Model 1
Model 2
Model 3
OR
95% CI
p-value
OR
95% CI
p-value
OR
95% CI
p-value
CysC, mg/L
3.40
1.95–5.95
<0.001
3.15
1.80–5.51
<0.001
3.90
2.12–7.31
<0.001
CysC (z-score)
1.43
1.22–1.68
<0.001
1.40
1.19–1.64
<0.001
1.49
1.24–1.79
<0.001
CysC quartiles
Q1
1.00 (Ref)
–
–
1.00 (Ref)
–
–
1.00 (Ref)
–
–
Q2
0.76
0.44–1.31
0.332
0.76
0.44–1.32
0.334
0.78
0.44–1.35
0.368
Q3
1.37
0.85–2.22
0.201
1.34
0.83–2.19
0.232
1.45
0.89–2.39
0.142
Q4
1.67
1.06–2.68
0.028
1.56
0.98–2.50
0.062
1.79
1.09–2.98
0.022
CysC, cystatin C; OR, Odds ratio; CI, confidence interval. Model 1: univarate. Model 2: adjusted for Gender, age, mean BMI, mean SBP. Model 3: Model 2 + marital status, physical activities, smoking habits, alcohol consumption, stroke, CHD, fasting blood glucose, triglyceride, LDL-C and eGFR. Bold p-values indicate statistically significant differences.
Multivariate adjusted ORs for the association between CysC levels and cognitive impairment in subgroups with and without albuminuria
Subgroup analyses were performed to examine the association between serum CysC and cognitive impairment across albuminuria-defined subgroups. Participants were categorized into albuminuria (n = 261) and non-albuminuria (n = 1,668) subgroups. Baseline characteristics of participants stratified by albuminuria status are shown in Supplementary Table S5. Cognitive impairment prevalence was 10.34% (27/261) in the albuminuria group and 7.31% (122/1668) in the non-albuminuria group. Participants with albuminuria exhibited a higher burden of comorbidities, including hypertension, diabetes, and dyslipidemia, along with elevated long-term systolic blood pressure (SBP), body mass index (BMI), fasting blood glucose (FBG), high-sensitivity C-reactive protein (hs-CRP), serum creatinine, and triglyceride levels, but lower HDL-C levels.
Results of the subgroup and interaction analyses by albuminuria status are presented in Table 3. In the non-albuminuria subgroup, each SD increase in CysC was significantly associated with greater odds of cognitive impairment after full adjustment (OR = 1.48, 95% CI: 1.22–1.80; p < 0.001). Participants in the highest CysC quartile had 1.75-fold greater odds of cognitive impairment compared with the lowest quartile (OR = 1.75, 95% CI: 1.03–3.03; p = 0.040). In the albuminuria subgroup, no significant associations between CysC and cognitive impairment were observed in any model. In the interaction analysis, the associations of both CysC levels and its z-score with cognitive impairment differed significantly according to albuminuria status (p for interaction = 0.028 for each). However, when CysC was analyzed in quartiles (Q1-Q4), albuminuria status did not significantly modify the association with cognitive impairment (p for interaction = 0.074).
ORs and 95% CIs of cognitive impairment in non-albuminuria subgroup and albuminuria subgroup.
Variable
Event/N
Model 1
Model 2
Model 3
OR
95% CI
p-value
OR
95% CI
p-value
OR
95% CI
p-value
Non-albuminuria subgroup
CysC, mg/L
122/1668 (7.23%)
3.83
2.07–7.24
<0.001
3.47
1.86–6.55
<0.001
3.86
2.01–7.58
<0.001
CysC (z-score)
1.48
1.24–1.78
<0.001
1.44
1.20–1.73
<0.001
1.48
1.22–1.80
<0.001
CysC quartiles
Q1
1.000 (Ref)
–
–
1.000 (Ref)
–
–
1.000 (Ref)
–
–
Q2
1.03
0.58–1.82
0.923
0.98
0.55–1.75
0.946
0.94
0.52–1.69
0.828
Q3
1.45
0.86–2.47
0.170
1.32
0.78–2.29
0.306
1.35
0.79–2.35
0.278
Q4
1.77
1.06–2.99
0.030
1.63
0.97–2.78
0.069
1.75
1.03–3.03
0.040
Albuminuria subgroup
CysC, mg/L
27/261 (8.43%)
1.27
0.48–2.58
0.545
1.26
0.47–2.62
0.564
0.99
0.34–2.18
0.981
CysC (z-score)
1.07
0.81–1.32
0.545
1.07
0.80–1.32
0.564
1.00
0.73–1.25
0.981
CysC quartiles
Q1
1.000 (Ref)
–
–
1.000 (Ref)
–
–
1.000 (Ref)
–
–
Q2
0.15
0.01–0.86
0.077
0.14
0.01–0.84
0.072
0.13
0.01–0.78
0.061
Q3
1.59
0.54–4.80
0.402
1.83
0.59–5.81
0.293
2.29
0.68–8.13
0.184
Q4
1.34
0.50–3.81
0.571
1.27
0.46–3.72
0.652
1.33
0.42–4.39
0.626
p for interaction of CysC
0.027
0.046
0.028
p for interaction of CysC (z_score)
0.027
0.046
0.028
p for interaction of CysC quartiles
0.137
0.107
0.074
CysC, cystatin C; OR, Odds ratio; CI, confidence interval. Model 1: univarate. Model 2: adjusted for Gender, age, mean BMI, mean SBP. Model 3: Model 2 + marital status, physical activities, smoking habits, alcohol consumption, stroke, CHD, fasting blood glucose, triglyceride, LDL-C and eGFR. Bold p-values indicate statistically significant differences.
The patterns of association derived from restricted cubic spline analyses are illustrated in Figure 2. A near-linear increasing trend with tight confidence bands was observed in all participants and the non-albuminuria subgroup, aligning with their significant linear p-values (both <0.001) and non-significant nonlinearity tests (p = 0.604 and 0.456). Conversely, the albuminuria subgroup displayed a potential non-linear (rising then falling) trend with broad confidence intervals. Statistically, neither linear nor nonlinear associations were significant in this subgroup (p for linearity >0.05, p for nonlinearity = 0.324). The precision of the estimate in this group was lower, as reflected by the wide CIs.
Nonlinear association of serum CysC with cognitive impairment across subgroups. Restricted cubic spline plots showing the association of serum cystatin C with the odds (log-scale) of cognitive impairment in a cross-sectional analysis. All models are adjusted for gender, age, mean BMI, mean SBP, marital status, physical activities, smoking habits, alcohol consumption, stroke, CHD, fasting blood glucose, triglyceride, LDL-C, and eGFR. (A) Total population. (B) Non-albuminuria subgroup. (C) Albuminuria subgroup.
Three-panel figure showing line graphs with shaded confidence intervals. Panel A displays odds ratio versus cystatin C (CysC) in mg/L with a significant overall P value less than 0.001 and P for nonlinearity 0.604, showing a rising trend. Panel B also shows a rising odds ratio with CysC, significant overall P value less than 0.001, and P for nonlinearity 0.456. Panel C indicates no significant relationship, with P for overall 0.424 and P for nonlinearity 0.324; the odds ratio line remains around one.Sensitivity analysis and subgroup analysis
Considering the potential confounding effects of antihypertensive, hypoglycemic, or lipid-lowering medications on renal and cognitive function, we excluded 283 participants with medication using (Supplementary Table S6). The association between CysC and cognitive impairment remained significant after the exclusion. In fully adjusted models, each SD increase in CysC was significantly associated with higher cognitive impairment risk (OR = 1.45, 95% CI: 1.18–1.81; p < 0.001). Participants in the highest CysC quartile exhibited 2.0-fold greater odds of impairment compared to the lowest quartile (OR = 2.01, 95% CI: 1.10–3.75; p = 0.024; Supplementary Table S7).
In the subgroup analyses, all covariates, except for the stratification variable itself, were adjusted for as potential confounders. Baseline characteristics of participants stratified by albuminuria status, sex, alcohol consumption, and hypertension status are presented in Supplementary Tables S8–S10, respectively. The associations of both CysC levels and its z-score with cognitive impairment are presented in Supplementary Figure S1. Subgroup analyses were performed according to sex, alcohol consumption status, and hypertension status. A per-SD increase in the CysC z-score remained significantly associated with greater odds of cognitive impairment across all prespecified subgroups: among men (adjusted OR = 1.58, 95% CI: 1.24–2.03) and women (OR = 1.34, 95% CI: 1.04–1.73); among alcohol consumers (OR = 2.23, 95% CI: 1.33–3.75) and non-consumers (OR = 1.41, 95% CI: 1.16–1.71); and among participants with hypertension (OR = 1.77, 95% CI: 1.31–2.39) and those without (OR = 1.39, 95% CI: 1.11–1.73; all p-values < 0.005). The interaction terms for these subgroup variables were not statistically significant (all p for interaction > 0.05), indicating that these factors did not significantly modify the main association.
Discussion
Our study demonstrates the association between CysC levels and cognitive impairment assessed by MMSE after comprehensive covariate adjustment in the midlife natural population from Hanzhong Adolescent Hypertension Cohort: Compared to the lowest CysC quartile, participants in the highest quartile showed a noteworthy elevation in the prevalence of cognitive impairment, and the association exhibits in participants without albuminuria in subgroup analysis.
The CysC-cognition association was substantially amplified in the hypertension population compared to normotensive individuals. It is in line with the previous conclusion that elevated blood pressure increases the risk of cognitive impairment, especially for population with hypertension and without renal damage (38–41). Furthermore, our analyses revealed amplified associations between elevated CysC levels and cognitive impairment in male participants and alcohol consumers. This underscores alcohol’s underrecognized role as a potential modifier of cognitive pathology (39, 42). A significant interaction was observed between CysC levels and albuminuria status, revealing that the association was more pronounced in individuals without albuminuria. Several non-mutually exclusive explanations may account for this observation. First, the albuminuria subgroup had a smaller sample size and fewer cognitive impairment events, resulting in wider confidence intervals and reduced statistical power to detect a significant association. Second, although we adjusted for eGFR, residual confounding from unmeasured factors, such as the severity of co-existing chronic conditions or systemic inflammation levels, may have obscured the relationship within the albuminuria group. Third, distinct biological mechanisms may operate at different stages of renal and vascular disease. In individuals without albuminuria, elevated CysC may primarily reflect early subclinical vascular injury or neuroinflammation, serving as a sensitive early marker for cognitive risk. In contrast, in individuals with established albuminuria—a marker of more advanced renal damage—cognitive impairment may be driven predominantly by stronger competing risk factors, such as the accumulation of uremic toxins or severe cardiovascular complications, thereby attenuating the measurable independent contribution of CysC.
Pacholko et al. (43–45) established elevated blood pressure as a well-documented risk factor for cognitive impairment, a conclusion consistent with our findings. The kidneys represent prime target organs for hypertension-induced damage (46–48), with albuminuria serving as a key biomarker of renal impairment (49, 50). These findings in subgroup analysis carry important clinical implications. For non-albuminuric patients, CysC monitoring may offer earlier detection of neuroinflammatory processes preceding cognitive decline. Our finding of a strong association between elevated CysC and cognitive impairment in the non-albuminuric subgroup suggests that, in populations with hypertension but without advanced renal damage, CysC may be a relevant biomarker of concurrent cerebrovascular burden. Future prospective studies are needed to determine if monitoring CysC levels over time can help identify individuals at a higher risk of progressive cognitive impairment.
In the early stages of hypertension, the condition is characterized by slightly elevated blood pressure and a short duration of illness. During this period, there is typically without renal damage. We hope that the conclusion of our research can raise more attention to cognitive impairment at this stage. A multicenter study pointed that exposure to higher BP levels from young to midlife is associated with worse cognitive function in midlife (32). Our study extends this paradigm by demonstrating that sustained BP elevation from adolescence through midlife exerts particularly detrimental effects. While the precise pathological mechanisms linking hypertension and cognitive decline remain incompletely characterized (33), we hypothesize a potential cerebrovascular pathway: chronic elevation in blood pressure may contribute to cerebral small vessel disease and blood–brain barrier dysfunction, processes in which CysC may serve as a biomarker. This hypothesis, if confirmed by longitudinal studies, would have two important implications: First, it would suggest that long-term BP trajectories might be more informative than single measurements in understanding the development of cognitive impairment. Second, it would underscore the potential importance of early-life cardiovascular health management for preserving cognitive function later in life. Future research with repeated measures is needed to directly test these possibilities.
The MMSE scale remains a classic screening tool for cognitive impairment. However, defining cognitive impairment solely by MMSE scores may increase false-positive identifications, potentially leading to inaccurate targeting of preventive interventions for dementia. To enhance diagnostic precision, our study defined cognitive impairment by integrating MMSE scores with educational attainment levels. This combined approach demonstrates improved accuracy and feasibility for identifying cognitive impairment in middle-aged and elderly Chinese populations with significant educational disparities—a methodology meriting broader implementation in other underdeveloped regions. However, a key limitation of our study is its reliance on the MMSE for defining cognitive impairment. The MMSE has well-recognized limitations, including ceiling effects in highly educated individuals and insensitivity to early or domain-specific cognitive decline, particularly in executive function and attention. This relative insensitivity likely results in non-differential misclassification, where some participants with genuine mild cognitive impairment are incorrectly classified as cognitively normal. Such misclassification typically biases the observed associations toward the null (attenuation), meaning that the true strength of the association between CysC and cognitive impairment may be stronger than what we reported. Other instruments, such as the Montreal Cognitive Assessment (MoCA), offer higher sensitivity for mild cognitive impairment, and the Digit Symbol Substitution Test (DSST) provides a more comprehensive assessment of attention and processing speed. However, given the large scale of our cohort, the participants’ generally low and heterogeneous educational backgrounds, and the practical constraints of field work in an underdeveloped region, the MMSE was chosen for its superior feasibility in large-scale population screening for cognitive impairment and dementia.
The relationship between CysC and cognitive function remains inconclusive (34). Contrary to our findings, GAUTHIER et al. proposed that CysC exerts protective effects against neurodegeneration, learning deficits, and cognitive impairment (34–36), with lower serum CysC levels associated with increased disease risk (37). However, the data in these prior studies are primarily derived from hospital-based patient cohorts, potentially introducing selection bias and confounding effects from underlying comorbidities on both CysC levels and cognitive function (51–53). Previous studies have demonstrated that elderly individuals aged 70–79 years with elevated CysC levels exhibited poorer MMSE and DSST scores, showing greater cognitive impairment over 7-year follow-up compared to those with lower CysC levels. BANG and GREGORY et al. suggested that cognitive impairment may originate in midlife, a view supported by the Lancet Commission’s recommendation to initiate dementia prevention during midlife (2). Our study focused on a middle-aged natural population with lower cognitive impairment prevalence. By combining MMSE scores with educational attainment, we established a methodology that enables more accurate and efficient identification of cognitive impairment in questionnaire-based screenings. Notably, the association between elevated CysC levels and cognitive impairment remained significant and was even stronger after stratification by albuminuria status, blood pressure, age, sex, and lifestyle factors. These subgroup analyses indicate that the association between CysC and cognitive impairment warrants renewed attention and broader clinical application.
American Academy of Neurology (AAN) (54–56) and the Lancet Commission (2) have reported insufficient evidence to recommend pharmacological interventions for mild cognitive impairment, with no proven cognition-enhancing effects from specific treatments. Blood-based biomarkers offer broader acceptability and applicability for detection (2), presenting potential advantages in cognitive impairment screening. As CysC is routinely screened in natural populations, we propose its elevation as an early warning biomarker for cognitive impairment risk. This approach demonstrates operational feasibility with minimal added public health burden. We recommend healthcare providers: Firstly, screen high-risk populations through CysC monitoring; Secondly, identify cognitive impairment using MMSE scores adjusted for educational attainment; Thirdly, guide at-risk individuals to modify risk factors (e.g., obesity, hypertension, alcohol overconsumption, air pollutants (2)). This integrated strategy may enable earlier detection of dementia and Alzheimer’s disease, thereby reducing the public health burden.
Our study has several limitations. First, as a single-center investigation, a larger sample size is required to refine the analytical models. Further research is needed to establish the critical threshold for CysC levels to enable precise identification of high-risk cognitive impairment populations. Second, cognitive impairment was defined using MMSE scores adjusted for educational attainment. This approach lacks the diagnostic specificity of specialized clinical assessments such as neuroimaging and electrophysiological examinations. Third, although this cohort was established in 1987, cognitive function assessments were primarily concentrated at the most recent follow-up in 2023. Extended longitudinal follow-up is necessary to elucidate the long-term impact of elevated CysC on cognitive trajectories. Finally, the absence of mechanistic studies limits biological validation. Based on established biochemical functions of CysC and existing evidence, we hypothesize its involvement in amyloid-β metabolism (57–59) and neuronal degeneration processes (60). However, this mechanistic explanation remains speculative and must be considered a hypothesis requiring validation through well-designed basic science experiments or dedicated long-term longitudinal studies.
Conclusion
In conclusion, our research found that Elevated CysC is associated with cognitive impairment assessed by MMSE in this midlife natural population cohort, and this association is exhibited stronger in participants without albuminuria. Furthermore, our subgroup analyses further highlight the heterogeneity of this association across different populations. Collectively, these findings underscore the potential importance of enhancing cognitive function screening among individuals with elevated CysC levels, with the aim of early identification of those at risk for Alzheimer’s disease and dementia.
Data availability statement
The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.
Ethics statement
The studies involving humans were approved by the Academic Committee of the First Affiliated Hospital of Xi'an Jiaotong University (Approval number: XJTU1AF2015LSL 047). The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study.
We sincerely thank the grassroots health staff in Hanzhong for assistance in the completion of follow-up process.
Conflict of interest
The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declared that Generative AI was not used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Supplementary material
The Supplementary material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fneur.2026.1739512/full#supplementary-material
ReferencesWorld Health Organization. Who Guidelines Approved by the Guidelines Review Committee. Risk reduction of cognitive decline and dementia: Who guidelines. Geneva: World Health Organization (2019).LivingstonGHuntleyJSommerladAAmesDBallardCBanerjeeS. Dementia prevention, intervention, and care: 2020 report of the lancet commission. Lancet. (2020) 396:413–46. doi: 10.1016/s0140-6736(20)30367-6, 32738937BaiWChenPCaiHZhangQSuZCheungT. Worldwide prevalence of mild cognitive impairment among community dwellers aged 50 years and older: a meta-analysis and systematic review of epidemiology studies. Age Ageing. (2022) 51:173. doi: 10.1093/ageing/afac173HillNTMowszowskiLNaismithSLChadwickVLValenzuelaMLampitA. Computerized cognitive training in older adults with mild cognitive impairment or dementia: a systematic review and meta-analysis. Am J Psychiatry. (2017) 174:329–40. doi: 10.1176/appi.ajp.2016.16030360, 27838936GregorySBuller-PeraltaIBridgemanKGóngoraVCDounaviMELowA. The Mediterranean diet is not associated with neuroimaging or cognition in middle-aged adults: a cross-sectional analysis of the prevent dementia Programme. Eur J Neurol. (2024) 31:e16345. doi: 10.1111/ene.16345, 38794967BatemanRJXiongCBenzingerTLFaganAMGoateAFoxNC. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med. (2012) 367:795–804. doi: 10.1056/NEJMoa1202753, 22784036AndersonND. State of the science on mild cognitive impairment (MCI). CNS Spectr. (2019) 24:78–87. doi: 10.1017/s1092852918001347, 30651152KianiL. A biomarker for mild cognitive impairment. Nat Rev Neurol. (2023) 19:459. doi: 10.1038/s41582-023-00849-4, 37402806WangCWangJZhuZHuJLinY. Spotlight on pro-inflammatory chemokines: regulators of cellular communication in cognitive impairment. Front Immunol. (2024) 15:1421076. doi: 10.3389/fimmu.2024.1421076, 39011039Réaux-Le GoazigoAVan SteenwinckelJRostèneWMélik ParsadaniantzS. Current status of chemokines in the adult cns. Prog Neurobiol. (2013) 104:67–92. doi: 10.1016/j.pneurobio.2013.02.001, 23454481PuLPanDWangHHeXZhangXYuZ. A predictive model for the risk of cognitive impairment in community middle-aged and older adults. Asian J Psychiatr. (2023) 79:103380. doi: 10.1016/j.ajp.2022.103380, 36495830GrubbASimonsenOSturfeltGTruedssonLThysellH. Serum concentration of cystatin C, factor D and Beta 2-microglobulin as a measure of glomerular filtration rate. Acta Med Scand. (1985) 218:499–503. doi: 10.1111/j.0954-6820.1985.tb08880.x, 3911736FuELLeveyASCoreshJElinderCGRotmansJIDekkerFW. Accuracy of Gfr estimating equations in patients with discordances between creatinine and cystatin C-based estimations. J Am Soc Nephrol. (2023) 34:1241–51. doi: 10.1681/asn.0000000000000128, 36995139DelgadoCBawejaMCrewsDCEneanyaNDGadegbekuCAInkerLA. A unifying approach for Gfr estimation: recommendations of the Nkf-Asn task force on reassessing the inclusion of race in diagnosing kidney disease. J Am Soc Nephrol. (2021) 32:2994–3015. doi: 10.1681/asn.2021070988, 34556489EbertNShlipakMG. Cystatin C is ready for clinical use. Curr Opin Nephrol Hypertens. (2020) 29:591–8. doi: 10.1097/mnh.0000000000000638, 32868529NairPMisraSNathMVibhaDSrivastavaAKPrasadK. Cystatin C and risk of mild cognitive impairment: a systematic review and meta-analysis. Dement Geriatr Cogn Disord. (2020) 49:471–82. doi: 10.1159/000510219, 33075778YangCGCaiSMLiuCYChenC. On the correlation between serum cystatin C and Parkinson’s disease in the Chinese population: a promising biomarker?J Integr Neurosci. (2021) 20:349–57. doi: 10.31083/j.jin2002034, 34258933ChuCDaiYMuJYangRWangMYangJ. Associations of risk factors in childhood with arterial stiffness 26 years later: the Hanzhong adolescent hypertension cohort. J Hypertens. (2017) 35:S10–s5. doi: 10.1097/hjh.0000000000001242, 28060189GuoTZhengSChenTChuCRenJSunY. The association of long-term trajectories of BMI, its variability, and metabolic syndrome: a 30-year prospective cohort study. EClinicalMedicine. (2024) 69:102486. doi: 10.1016/j.eclinm.2024.102486, 38370536ZhengWMuJChuCHuJYanYMaQ. Association of blood pressure trajectories in early life with subclinical renal damage in middle age. J Am Soc Nephrol. (2018) 29:2835–46. doi: 10.1681/asn.2018030263, 30420422WangYZhaoPChuCDuMFZhangXYZouT. Associations of long-term visit-to-visit blood pressure variability with subclinical kidney damage and albuminuria in adulthood: a 30-year prospective cohort study. Hypertension. (2022) 79:1247–56. doi: 10.1161/hypertensionaha.121.18658, 35360932NiuZJYaoSZhangXMuJJDuMFZouT. Associations of genetic variations in Nedd4l with salt sensitivity, blood pressure changes and hypertension incidence in Chinese adults. J Clin Hypertens (Greenwich). (2022) 24:1381–9. doi: 10.1111/jch.14566, 36039789Writing Goup of the Dementia and Cognitive Society of Neurology Committee of Chinese Medical Association, Alzheimer’s Disease Chinese. Guidelines for dementia and cognitive impairment in China: the diagnosis and treatment of mild cognitive impairment. Zhonghua Yi Xue Za Zhi. (2010) 90:2887–93. 21211391WangYLiFChuCZhangXZhangXYLiaoYY. Early life body mass index trajectories and albuminuria in midlife: a 30-year prospective cohort study. EClinicalMedicine. (2022) 48:101420. doi: 10.1016/j.eclinm.2022.101420, 35516445WangYWangJZhengXWDuMFZhangXChuC. Early-life cardiovascular risk factor trajectories and vascular aging in midlife: a 30-year prospective cohort study. Hypertension. (2023) 80:1057–66. doi: 10.1161/hypertensionaha.122.20518, 36880389YanYWangDSunYMaQWangKLiaoY. Triglyceride-glucose index trajectory and arterial stiffness: results from Hanzhong adolescent hypertension cohort study. Cardiovasc Diabetol. (2022) 21:33. doi: 10.1186/s12933-022-01453-4, 35216614LiHJiaJYangZ. Mini-mental state examination in elderly Chinese: a population-based normative study. J Alzheimer's Dis. (2016) 53:487–96. doi: 10.3233/jad-160119, 27163822XuGMeyerJSHuangYDuFChowdhuryMQuachM. Adapting mini-mental state examination for dementia screening among illiterate or minimally educated elderly Chinese. Int J Geriatr Psychiatry. (2003) 18:609–16. doi: 10.1002/gps.890, 12833305KatzmanRZhangMYOuang YaQWangZYLiuWTYuE. A Chinese version of the mini-mental state examination; impact of illiteracy in a Shanghai dementia survey. J Clin Epidemiol. (1988) 41:971–8. doi: 10.1016/0895-4356(88)90034-0ChenCLiuGChuCZhengWMaQLiaoY. A novel and noninvasive risk assessment score and its child-to-adult trajectories to screen subclinical renal damage in middle age. Bioengineering. (2023) 10:257. doi: 10.3390/bioengineering10020257, 36829751YanYZhengWMaQChuCHuJWangK. Child-to-adult body mass index trajectories and the risk of subclinical renal damage in middle age. Int J Obes. (2021) 45:1095–104. doi: 10.1038/s41366-021-00779-5, 33608649MahinradSKurianSGarnerCRSedaghatSNemethAJMoscufoN. Cumulative blood pressure exposure during young adulthood and mobility and cognitive function in midlife. Circulation. (2020) 141:712–24. doi: 10.1161/circulationaha.119.042502WalkerKAPowerMCGottesmanRF. Defining the relationship between hypertension, cognitive decline, and dementia: a review. Curr Hypertens Rep. (2017) 19:24. doi: 10.1007/s11906-017-0724-3, 28299725MathewsPMLevyE. Cystatin C in aging and in Alzheimer's disease. Ageing Res Rev. (2016) 32:38–50. doi: 10.1016/j.arr.2016.06.003, 27333827GauthierSKaurGMiWTizonBLevyE. Protective mechanisms by cystatin C in neurodegenerative diseases. Front Biosci (Schol Ed). (2011) 3:541–54. doi: 10.2741/s170, 21196395LiuYLiJWangZYuZChenG. Attenuation of early brain injury and learning deficits following experimental subarachnoid hemorrhage secondary to cystatin C: possible involvement of the autophagy pathway. Mol Neurobiol. (2014) 49:1043–54. doi: 10.1007/s12035-013-8579-3, 24203677SundelöfJArnlövJIngelssonESundströmJBasuSZetheliusB. Serum cystatin C and the risk of Alzheimer disease in elderly men. Neurology. (2008) 71:1072–9. doi: 10.1212/01.wnl.0000326894.40353.93AsmujeNFMatSMyintPKTanMP. Blood pressure variability and cognitive function: a scoping review. Curr Hypertens Rep. (2022) 24:375–83. doi: 10.1007/s11906-022-01200-w, 35731334De FalcoEWhiteSMMorningstarMDMaBNkurunzizaLTAhmed-DilibeA. Impaired cognitive flexibility and heightened urgency are associated with increased alcohol consumption in rodent models of excessive drinking. Addict Biol. (2021) 26:e13004. doi: 10.1111/adb.13004, 33508872LandeMBKupfermanJC. Blood pressure and cognitive function in children and adolescents. Hypertension. (2019) 73:532–40. doi: 10.1161/hypertensionaha.118.11686, 30686086ZhengGZhouBFangZChenXLiuMHeF. Long-term visit-to-visit blood pressure variability and cognitive decline among patients with hypertension: a pooled analysis of 3 national prospective cohorts. J Am Heart Assoc. (2024) 13:e035504. doi: 10.1161/jaha.124.035504, 38934858UenoFMatsushitaSHaraSOshimaSRohSRamchandaniVA. Influence of alcohol and acetaldehyde on cognitive function: findings from an alcohol clamp study in healthy young adults. Addiction. (2022) 117:934–45. doi: 10.1111/add.15733, 34735038PacholkoAIadecolaC. Hypertension, neurodegeneration, and cognitive decline. Hypertension. (2024) 81:991–1007. doi: 10.1161/hypertensionaha.123.21356, 38426329OuYNTanCCShenXNXuWHouXHDongQ. Blood pressure and risks of cognitive impairment and dementia: a systematic review and Meta-analysis of 209 prospective studies. Hypertension. (2020) 76:217–25. doi: 10.1161/hypertensionaha.120.14993, 32450739LennonMJLamBCPLipnickiDMCrawfordJDPetersRSchutteAE. Use of Antihypertensives, blood pressure, and estimated risk of dementia in late life: an individual participant data Meta-analysis. JAMA Netw Open. (2023) 6:e2333353. doi: 10.1001/jamanetworkopen.2023.33353, 37698858MesserliFHWilliamsBRitzE. Essential hypertension. Lancet. (2007) 370:591–603. doi: 10.1016/s0140-6736(07)61299-9, 17707755RitzENowickiMFliserDHörnerDKlimmHP. Proteinuria and hypertension. Kidney Int Suppl. (1994) 47:S76–80. 7869676LinYP. Albuminuria in hypertension. Hypertens Res. (2013) 36:762–4. doi: 10.1038/hr.2013.76LeonciniGViazziFParodiDVettorettiSRattoERaveraM. Mild renal dysfunction and subclinical cardiovascular damage in primary hypertension. Hypertension. (2003) 42:14–8. doi: 10.1161/01.Hyp.0000075789.58883.73LositoAFortunatiFZampiIDel FaveroA. Impaired renal functional reserve and albuminuria in essential hypertension. Br Med J (Clin Res Ed). (1988) 296:1562–4. doi: 10.1136/bmj.296.6636.1562, 3135009YaffeKKurella-TamuraMAckersonLHoangTDAndersonAHDuckworthM. Higher levels of cystatin C are associated with worse cognitive function in older adults with chronic kidney disease: the chronic renal insufficiency cohort cognitive study. J Am Geriatr Soc. (2014) 62:1623–9. doi: 10.1111/jgs.12986, 25125225WestreichD. Berkson's Bias, selection Bias, and missing data. Epidemiology. (2012) 23:159–64. doi: 10.1097/EDE.0b013e31823b6296, 22081062KodlCTSeaquistER. Cognitive dysfunction and diabetes mellitus. Endocr Rev. (2008) 29:494–511. doi: 10.1210/er.2007-0034, 18436709PetersenRCLopezOArmstrongMJGetchiusTSDGanguliMGlossD. Practice guideline update summary: mild cognitive impairment: report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology. Neurology. (2018) 90:126–35. doi: 10.1212/wnl.0000000000004826PetersenRCStevensJCGanguliMTangalosEGCummingsJLDeKoskyST. Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the quality standards subcommittee of the American Academy of Neurology. Neurology. (2001) 56:1133–42. doi: 10.1212/wnl.56.9.1133LarsonEB. Guideline: in patients with mild cognitive impairment, the Aan recommends regular exercise and no drugs or supplements. Ann Intern Med. (2018) 168:Jc38. doi: 10.7326/acpjc-2018-168-8-038, 29677245HaanJMaat-SchiemanMLvan DuinenSGJenssonOThorsteinssonLRoosRA. Co-localization of beta/A4 and cystatin C in cortical blood vessels in Dutch, but not in Icelandic hereditary cerebral hemorrhage with amyloidosis. Acta Neurol Scand. (1994) 89:367–71. doi: 10.1111/j.1600-0404.1994.tb02648.x, 8085435MaruyamaKKametaniFIkedaSIshiharaTYanagisawaN. Characterization of amyloid fibril protein from a case of cerebral amyloid Angiopathy showing Immunohistochemical reactivity for both Beta protein and cystatin C. Neurosci Lett. (1992) 144:38–42. doi: 10.1016/0304-3940(92)90710-o, 1436711MiWJungSSYuHSchmidtSDNixonRAMathewsPM. Complexes of amyloid-Beta and Cystatin C in the human central nervous system. J Alzheimer's Dis. (2009) 18:273–80. doi: 10.3233/jad-2009-1147, 19584436IshimaruHIshikawaKOheYTakahashiAMaruyamaY. Cystatin C and apolipoprotein E immunoreactivities in Ca1 neurons in ischemic gerbil Hippocampus. Brain Res. (1996) 709:155–62. doi: 10.1016/0006-8993(95)01232-x, 8833751
Edited by: Shihao He, Johns Hopkins University, United States
Reviewed by: Chenhui Mao, Peking Union Medical College Hospital (CAMS), China